Compare Marex Group Limited Ordinary Shares (MRX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marex Group Limited Ordinary Shares vs Repligen Corporation Common Stock — how do they compare? Marex Group Limited Ordinary Shares trades at $68.92 (market cap $4.99B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 2.3× Marex Group Limited Ordinary Shares's market cap, and Marex Group Limited Ordinary Shares pays a 0.92% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marex Group Limited Ordinary Shares for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| MRX | RGEN | |
|---|---|---|
Market Cap | $4.99B | $11.31B |
Volume | 779,593 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $78.27 | $194.57 |
52-Week Low | $29.92 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $8.07B | $11.20B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRX trades at $71.95, down 0.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a P/E of 14.62 and robust profitability, including a 9.69% net income margin and 27.57% ROE. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.64 surpassing the $1.36 estimate. Positive news includes record H1 2026 results and strategic developments in financial infrastructure.
The outlook for MRX is positive, supported by strong earnings momentum, a 100% buy rating from analysts, and a consensus price target of $83.67 implying significant upside. Key risks include execution of its acquisition strategy and market volatility. The stock's current valuation and growth trajectory present a compelling opportunity, though investors should monitor debt levels and competitive pressures.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marex Group Limited Ordinary Shares
Marex Group provides financial services across commodities, financial markets, and corporate clients. Its services include clearing, agency and execution, market making, hedging, and securities services.
Read more on MRX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
